» Articles » PMID: 34603340

Where Epigenetics Meets Food Intake: Their Interaction in the Development/Severity of Gout and Therapeutic Perspectives

Overview
Journal Front Immunol
Date 2021 Oct 4
PMID 34603340
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Gout is the most frequent form of inflammatory arthritis in the world. Its prevalence is particularly elevated in specific geographical areas such as in the Oceania/Pacific region and is rising in the US, Europe, and Asia. Gout is a severe and painful disease, in which co-morbidities are responsible for a significant reduction in life expectancy. However, gout patients remain ostracized because the disease is still considered "self-inflicted", as a result of unhealthy lifestyle and excessive food and alcohol intake. While the etiology of gout flares is clearly associated with the presence of monosodium urate (MSU) crystal deposits, several major questions remain unanswered, such as the relationships between diet, hyperuricemia and gout flares or the mechanisms by which urate induces inflammation. Recent advances have identified gene variants associated with gout incidence. Nevertheless, genetic origins of gout combined to diet-related possible uric acid overproduction account for the symptoms in only a minor portion of patients. Hence, additional factors must be at play. Here, we review the impact of epigenetic mechanisms in which nutrients (such as ω-3 polyunsaturated fatty acids) and/or dietary-derived metabolites (like urate) trigger anti/pro-inflammatory responses that may participate in gout pathogenesis and severity. We propose that simple dietary regimens may be beneficial to complement therapeutic management or contribute to the prevention of flares in gout patients.

Citing Articles

The changing burden of gout in adults aged 70 and above based on the global burden of disease 2019.

Yang Y, Liu Z Front Public Health. 2025; 13:1455726.

PMID: 39980931 PMC: 11840442. DOI: 10.3389/fpubh.2025.1455726.


Epigenetics-targeted drugs: current paradigms and future challenges.

Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S Signal Transduct Target Ther. 2024; 9(1):332.

PMID: 39592582 PMC: 11627502. DOI: 10.1038/s41392-024-02039-0.


Mechanism of macrophages in gout: Recent progress and perspective.

Tan H, Zhang S, Liao J, Qiu X, Zhang Z, Wang Z Heliyon. 2024; 10(19):e38288.

PMID: 39386881 PMC: 11462003. DOI: 10.1016/j.heliyon.2024.e38288.


Effect of low-purine diet on the serum uric acid of gout patients in different clinical subtypes: a prospective cohort study.

Chen Z, Xue X, Ma L, Zhou S, Li K, Wang C Eur J Med Res. 2024; 29(1):449.

PMID: 39223686 PMC: 11370010. DOI: 10.1186/s40001-024-02012-1.


Revisiting the Immunometabolic Basis for the Metabolic Syndrome from an Immunonutritional View.

Apaza C, Cerezo J, Garcia-Tejedor A, Gimenez-Bastida J, Laparra-Llopis J Biomedicines. 2024; 12(8).

PMID: 39200288 PMC: 11352112. DOI: 10.3390/biomedicines12081825.


References
1.
So A, Martinon F . Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017; 13(11):639-647. DOI: 10.1038/nrrheum.2017.155. View

2.
Benn C, Dua P, Gurrell R, Loudon P, Pike A, Storer R . Physiology of Hyperuricemia and Urate-Lowering Treatments. Front Med (Lausanne). 2018; 5:160. PMC: 5990632. DOI: 10.3389/fmed.2018.00160. View

3.
Royston K, Paul B, Nozell S, Rajbhandari R, Tollefsbol T . Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms. Exp Cell Res. 2018; 368(1):67-74. PMC: 6733260. DOI: 10.1016/j.yexcr.2018.04.015. View

4.
Guillen A, Te Karu L, Singh J, Dalbeth N . Gender and Ethnic Inequities in Gout Burden and Management. Rheum Dis Clin North Am. 2020; 46(4):693-703. DOI: 10.1016/j.rdc.2020.07.008. View

5.
Qin W, Zhang K, Clarke K, Weiland T, Sauter E . Methylation and miRNA effects of resveratrol on mammary tumors vs. normal tissue. Nutr Cancer. 2014; 66(2):270-7. DOI: 10.1080/01635581.2014.868910. View